Evidence map›Paper›PMID 31587039›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020

Pneumococcal Urinary Antigen Testing in United States Hospitals: A Missed Opportunity for Antimicrobial Stewardship.

Jennifer J Schimmel, Sarah Haessler, Peter Imrey, Peter K Lindenauer, Sandra S Richter, Pei-Chun Yu, Michael B Rothberg

2 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05568654 nacompletednot on this mapstarted 2022, after this paper: background citation

Reducing Antimicrobial Overuse Through Targeted Therapy for Patients With Community-Acquired Pneumonia

TypeinterventionalSponsorThe Cleveland ClinicRan2022 to 2026Enrolled28,580ConditionsCommunity-Acquired Pneumonia, Antimicrobial Stewardship, Point-of-Care TestingArmsRapid Diagnostic Testing, Pharmacist-led de-escalation
NCT05681156 completednot on this mapstarted 2023, after this paper: background citation

Curian S. Pneumo/Legionella Assay Beta Clinical Trial Protocol

TypeobservationalSponsorMeridian Bioscience, Inc.Ran2023 to 2023Enrolled199ConditionsStreptococcus Pneumoniae Infection, Legionella Pneumophila Serogroup 1 InfectionArmsN/A- There is no intervention.
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Challenges and opportunities in the management of severe pneumonia. Key concepts from the Seventh Annual Meeting of Spanish Experts 2025.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026
    Review
  3. Article
  4. Impact of pneumococcal urinary antigen testing on clinical outcomes in patients hospitalized with community-acquired pneumonia.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Article
  5. Article
  6. Towards a holistic approach to pulmonary infections. Insights from the Sixth Annual Meeting of Spanish Experts 2024.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025
    Review
  7. Things We Do for No Reason - OrderingOpen forum infectious diseases · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Impact ofOpen forum infectious diseases · 2022
    Article
  12. Article
  13. Review
  14. A Reappraisal of Streptococcal Urinary Antigen Testing for Antibiotic Stewardship.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  15. Review
  16. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Jennifer J SchimmelDivision of Infectious Diseases, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts, USA.
Sarah HaesslerDivision of Infectious Diseases, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts, USA.
Peter ImreyQuantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
Peter K LindenauerInstitute for Healthcare Delivery and Population Science and Department of Medicine, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts, USA.
Sandra S RichterDepartment of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Pei-Chun YuQuantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
Michael B RothbergCleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Cleveland Clinic · USUniversity of Massachusetts Chan Medical School · USBaystate Medical Center · USCase Western Reserve University · USCleveland Clinic Lerner College of Medicine · US

Funding

Reducing Antimicrobial Overuse in HCAP Through Personalized Antimicrobial RecommendationsR01HS024277 · AHRQ · CLEVELAND CLINIC FOUNDATION · PI ROTHBERG, MICHAEL B · 2015 to 2019
$2.5M
AHRQ HHS R01 HS024277
6 · The paper itself

Abstract

backgroundThe Infectious Diseases Society of America recommends pneumococcal urinary antigen testing (UAT) when identifying pneumococcal infection would allow for antibiotic de-escalation. However, the frequencies of UAT and subsequent antibiotic de-escalation are unknown.

methodsWe conducted a retrospective cohort study of adult patients admitted with community-acquired or healthcare-associated pneumonia to 170 US hospitals in the Premier database from 2010 to 2015, to describe variation in UAT use, associations of UAT results with antibiotic de-escalation, and associations of de-escalation with outcomes.

resultsAmong 159 894 eligible admissions, 24 757 (15.5%) included UAT performed (18.4% of intensive care unit [ICU] and 15.3% of non-ICU patients). Among hospitals with ≥100 eligible patients, UAT proportions ranged from 0% to 69%. Compared to patients with negative UAT, 7.2% with positive UAT more often had a positive Streptococcus pneumoniae culture (25.4% vs 1.9%, P < .001) and less often had resistant bacteria (5.2% vs 6.8%, P < .05). Of patients initially treated with broad-spectrum antibiotics, most were still receiving broad-spectrum therapy 3 days later, but UAT-positive patients more often had coverage narrowed (38.4% vs 17.0% UAT-negative and 14.6% untested patients, P < .001). Hospital rate of UAT was strongly correlated with de-escalation following a positive test. Only 3 patients de-escalated after a positive UAT result were subsequently admitted to ICU.

conclusionsUAT is not ordered routinely in pneumonia, even in ICU. A positive UAT result was associated with less frequent resistant organisms, but usually did not lead to antibiotic de-escalation. Increasing UAT and narrowing therapy after a positive UAT result are opportunities for improved antimicrobial stewardship.

Indexed as

Antimicrobial StewardshipCommunity-Acquired InfectionsPneumonia, PneumococcalAdultAnti-Bacterial AgentsHospitalsHumansRetrospective StudiesStreptococcus pneumoniaeUnited StatesAnti-Bacterial Agentsantimicrobial stewardshipcommunity-acquired pneumoniaurinary antigen testing

Identifiers

PMID31587039
PMCPMC7901240
OpenAlexW2978222287

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.